Merck pulls a patent win for diabetes franchise in West Virginia federal court

Merck doesn’t have to sweat Januvia and Janumet competitors — at least for now.

A federal judge awarded Merck a win in its patent battle against Viatris, the pharma giant announced Thursday, putting the freeze on a potential Viatris generic until at least 2026, barring an appeal.